Dare Bioscience (US:DARE) — Company Overview, News & Financial Data
Dare Bioscience focuses on women's reproductive health, advancing innovative products across various life stages.
About Dare Bioscience
Dare Bioscience (NASDAQ:DARE) is a biopharmaceutical company focused on women's reproductive health. By advancing innovative products for women, Dare aims to improve their well-being across various life stages, addressing needs in contraception, vaginal health, fertility, and sexual health. The company's diverse portfolio includes clinical-stage drug projects designed to provide better treatment options and enhance quality of life. Through research and partnerships, Dare Bioscience is committed to delivering groundbreaking therapies that can fulfill unmet medical needs for women around the globe, thereby achieving its mission to revolutionize women's healthcare.
Snapshot
Operations
Products and/or services of Dare Bioscience
- Ovaprene, a non-hormonal, monthly contraceptive designed to provide a mixture of spermicides within a vaginal ring.
- Sildenafil Cream, 3.6%, a novel topical treatment aimed at enhancing female sexual arousal by increasing blood flow.
- XACIATO (Clindamycin Phosphate Vaginal Gel, 2%), developed for the treatment of bacterial vaginosis in female patients.
- DARE-HRT1, a bioidentical combination of estradiol and progesterone in a single, intravaginal ring for hormone therapy.
- DARE-FRT1, targeting the development of a formulation for ovarian hormone replacement therapy in women suffering from premature ovarian insufficiency.
- DARE-RH1, an investigational nasal spray for the treatment of reproductive health issues, leveraging a novel delivery system.
Dare Bioscience executive team
- Ms. Sabrina Martucci JohnsonCEO, President, Principal Financial Officer, Secretary & Director
- Ms. MarDee J. Haring-LaytonChief Accounting Officer
- Mr. Mark WaltersVice President of Operations
- Dr. David Friend Ph.D.Chief Scientific Officer
- Jennifer KiangVice President of Corporate Affairs & Development